This six-part series was written in collaboration with Kirsten Angeles and input from James Smith. You should find it particularly useful if you don’t know much about drug development yet and want to get a comprehensive overview.
Knowledge about drug development is often fragmented, expensive, and jargon-heavy. With this series we don’t want to debate the pros and cons of the system’s overall value; we want to explain how it works and how it came to work like this. The articles below aim to provide a comprehensive but concise introduction to all pharma’s essential stakeholders, processes, and principles, connecting them to actionable insights and further resources:
Drug Development Explainer Series
Link post
This six-part series was written in collaboration with Kirsten Angeles and input from James Smith. You should find it particularly useful if you don’t know much about drug development yet and want to get a comprehensive overview.
Knowledge about drug development is often fragmented, expensive, and jargon-heavy. With this series we don’t want to debate the pros and cons of the system’s overall value; we want to explain how it works and how it came to work like this. The articles below aim to provide a comprehensive but concise introduction to all pharma’s essential stakeholders, processes, and principles, connecting them to actionable insights and further resources:
Stakeholders in Drug Development
The Blueprint of Drug Development
Origins of Drug Regulation
Recommended Literature and Courses
Alvea: A Case Study of the Fastest Biotech to Go to In-Human Trials
Conclusions
Total read time is 45-60min.